Chemomab Therapeutics Ltd. (CMMB) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.25

From 52W high−65.59%

Volume36477.00

Market cap$8.57M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.25

From 52W high

−65.59%

Volume

36477.00

Market cap

$8.57M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

27.9

MomentumView details →

1D Return

−7.51%

YTD Return

−27.27%

SummaryUpdated Jun 1, 2026

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is a clinical-stage biotechnology company founded in 2011 and headquartered in Tel Aviv, Israel. The company went public in February 2019 and was formerly known as Anchiano Therapeutics Ltd. before changing its name to Chemomab Therapeutics in March 2021. Chemomab focuses on developing innovative therapeutics for the treatment of inflammation and fibrosis, conditions that affect millions of patients worldwide and represent significant unmet medical needs.

Ask drillr about Chemomab Therapeutics Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−87.53%

ROA (TTM)

−74.25%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+56.96%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+97.94%

EBITDA YoY

+37.31%

MomentumView details →

1D Return

−7.51%

YTD Return

−27.27%

1Y Return

−64.71%

RSI (14)

27.9

vs 50D SMA

−41.62%

vs 200D SMA

−32.83%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

6.41x

Quick Ratio

6.41x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.27

EPS Surprise

−80.00%

Beats (12Q)

5/12

Next Q EPS Est

−$0.01

Avg Surprise (4Q)

−212.50%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−7.60M

Op. CF (TTM)

−11.22M

Next earningsNov 6, 2026 →

Latest newsMore news →

Chemomab Therapeutics announced that its planned merger with Scipher Medicine is advancing, with closing expected by year-end.62d ago

Chemomab Therapeutics announced its second quarter 2026 financial results and provided a corporate update.62d ago

Similar companies

COSCIENS Biopharma Inc.CSCI Brainstorm Cell Therapeutics Inc.BCLI enGene Holdings Inc. WarrantsENGNW VistaGen Therapeutics, Inc.VTGN MetaVia Inc.MTVA Alaunos Therapeutics, Inc.TCRT Find similar companies →

Latest newsMore news →

Chemomab Therapeutics announced that its planned merger with Scipher Medicine is advancing, with closing expected by year-end.62d ago Chemomab Therapeutics announced its second quarter 2026 financial results and provided a corporate update.62d ago